Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants
- 1 January 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 18 (1) , 113-120
- https://doi.org/10.1158/1055-9965.epi-08-0591
Abstract
Human papillomavirus (HPV) cofactors for cervical cancer include smoking, multiparity, and oral contraceptive use, but their mechanisms of action are not fully understood. It is also unknown whether cofactors vary by HPV genotypes. The Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) is a cross-sectional study comprising women referred to the University of Oklahoma from November 2003 to September 2007 for abnormal cervical screening results. Detailed questionnaire data and liquid cytology specimens were collected and the latter was genotyped for HPV using the LINEAR ARRAY HPV Genotyping Test. The present analysis includes women with both questionnaire and HPV data and diagnosed with n = 535), CIN1 (n = 497), CIN2 (n = 336), CIN3 (n = 292), and cancer (n = 80). We evaluated HPV types and cofactors among HPV-infected women by calculating odds ratios (OR) and 95% confidence intervals (95% CI) for CIN3 and CIN2 separately compared with <CIN2 using a polytomous logistic regression model; cancers were excluded from further analysis due to the substantially higher ages of these women. We found that HPV-infected women with minor histologic or cytologic abnormalities (e.g., CIN1, ASCUS, and LSIL) were indistinguishable from those with normal histology/cytology and were thus combined to form the referent group (<CIN2). Among women positive for oncogenic HPV, current smokers had a 2.5-fold increased risk for CIN3 (95% CI, 1.8-3.6) compared with nonsmokers. Among HPV16-infected women, current smokers had elevated risk for both CIN2 (OR, 1.9; 95% CI, 1.1-3.2) and CIN3 (OR, 2.7; 95% CI, 1.6-4.6). Our data suggest that non-HPV16-related CIN2 likely reflects a combination of CIN1 and CIN3 diagnosis, whereas HPV16-related CIN2 may indicate a precancerous state. Investigations on the molecular distinctions along the disease continuum of cervical pathogenesis by HPV type are needed. (Cancer Epidemiol Biomarkers Prev 2009;18(1):113–20)Keywords
This publication has 29 references indexed in Scilit:
- CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3International Journal of Gynecological Pathology, 2007
- DNA extraction: An understudied and important aspect of HPV genotyping using PCR-based methodsJournal of Virological Methods, 2007
- Cervical Tissue Collection Methods for RNA Preservation: Comparison of Snap-frozen, Ethanol-fixed, and RNAlater-fixationDiagnostic Molecular Pathology, 2006
- Chapter 1: HPV in the etiology of human cancerVaccine, 2006
- Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studiesInternational Journal of Cancer, 2006
- Towards Improved Biomarker Studies of Cervical NeoplasiaDiagnostic Molecular Pathology, 2005
- Epidemiologic and viral factors associated with cervical neoplasia in HPV‐16‐positive womenInternational Journal of Cancer, 2005
- ASCUS-LSIL Triage StudyActa Cytologica, 2000
- Inter-observer variation in cytological and histological diagnoses of cervical neoplasia and its epidemiologic implicationJournal of Clinical Epidemiology, 1995
- The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute WorkshopPublished by American Medical Association (AMA) ,1989